A new antibiotic will soon be approved for skin and soft tissue infections (SSTIs): dalbavancin. The company behind the drug will likely begin marketing heavily to emergency physicians as many patients with SSTIs seek care in the Emergency Department (ED). However, should we seriously consider dalbavancin as an addition to an ED’s arsenal against SSTIs and should it change our practice?
The acute episode of intoxication and agitation has subsided and your patient is calm. She has been medically cleared and is ready to be moved to a less acute, less monitored portion of the ED to await further assessment and treatment for her underlying psychiatric conditions. As a well-intentioned emergency medicine practitioner, you wish to give your patient the tools she needs to maintain this calm status by restarting her home atypical antipsychotic medication. What is the best way to go about doing this?
While the atypical antipsychotics have generally been considered safer than the first generation agents due to the decreased risk of extrapyramidal side effects at therapeutic doses, this class is not without adverse effects. All of the medications in this class are capable of causing sedation due to their antihistaminergic effects and some of these agents also have an alpha-blockade effect possibly leading to orthostatic hypotension.1
When faced with the prospect of re-initiation of atypical antipsychotics, it is necessary to determine how long the patient has been without medication if possible. While there is a lack of literature regarding this topic, select medications make reference to re-initiation in their package inserts.2–4 These recommendations range from “an interval off” to “more than one week”, possibly indicating that a few missed doses may not have an impact on the re-initiation dose. However, when it is determined that a patient has been without their atypical antipsychotic for a few days to a week or the period of nonadherence is unknown, caution with re-initiation is justified and some package inserts call for restarting the initial dosing titration.
| Medication | Package insert: Day 1 dosing | Re-initiation recommendation |
|---|---|---|
| Aripiprazole (Abilify) | Schizophrenia: 10-15 mg PO Q 24 hours Bipolar mania: 15 mg PO Q 24 hours Bipolar mania (adjunctive therapy): 10-15 mg PO Q 24 hours | No recommendations |
| Asenapine (Saphris) | Schizophrenia: 5 mg PO Q 12 hours Bipolar mania (monotherapy): 10 mg PO Q 12 hours Bipolar mania (adjunctive therapy): 5 mg PO Q 12 hours | No recommendations |
| Iloperidone (Fanapt) | Schizophrenia: 1 mg PO Q 12 hours | When off > 3 days, the initial dosing titration schedule should be followed |
| Lurasidone (Latuda) | Schizophrenia: 40 mg PO Q 24 hours Bipolar depression: 20 mg PO Q 24 hours | No recommendations |
| Olanzapine (Zyprexa) | Schizophrenia: 5-10 mg PO Q 24 hours Bipolar disorder: 10-15 mg PO Q 24 hours | No recommendations |
| Paliperidone (Invega) | Schizophrenia: 6 mg PO Q 24 hours Schizoaffective disorder: 6 mg PO Q 24 hours | No recommendations |
| Quetiapine (Seroquel) | Schizophrenia: 25 mg PO Q 12 hours Bipolar mania: 50 mg PO Q 12 hours Bipolar depression: 50 mg PO Q HS | When off ≥ 1 week, the initial dosing titration schedule should be followed |
| Risperidone (Risperdal) | Schizophrenia: 2 mg PO Q 24 hours Bipolar mania: 2-3 mg PO Q 24 hours | When off for an interval, the initial titration schedule should be followed |
| Ziprasidone (Geodon) | Schizophrenia: 20 mg PO Q 12 hours Bipolar I disorder: 40 mg PO Q12 hours | No recommendations |
| * Dosing above is not adjusted for renal or hepatic dysfunction or concomitantly administered interacting medications | ||
Due to the risk of agranulocytosis for which there is a black box warning, all patients prescribed clozapine must be enrolled in a registry which monitors the patient’s white blood cell count and absolute neutrophil count. As a result, clozapine dosing must be made in collaboration with the patient’s clozapine registry. In addition, clozapine also carries a black box warning for cardiovascular and respiratory effects and states that for patients who have been without clozapine for 2 or more days, they are to start with 12.5 mg once or twice daily.5
For other agents, the course of action is less clear. Dosing decisions should ideally be made in conjunction with a psychiatric care provider; however this is not always feasible in the ED setting. For patients on atypical antipsychotics without clear re-initiation instructions in the prescribing information and doses higher than initial dosing (see table), consider a dose reduction. Anecdotally, re-initiating the dose at 50-80% of the maintenance dose seems reasonable in hemodynamically stable patients; however, there are not identified data to support this strategy. Regardless of the strategy implored, vigilance is important when re-initiating atypical antipsychotics. This is especially noteworthy in patients who will be in a less monitored area of the department.
Reviewer: Clayton English, PharmD, BCPP
Sometimes, in an effort to make things simpler, we actually make them more confusing. Such is the case with phenytoin equivalents.
Fosphenytoin is a water-soluble prodrug of phenytoin. After IV administration, much of the fosphenytoin is metabolized to phenytoin within 15 minutes. Advantages over phenytoin include the option for IM administration and less cardiotoxicity allowing for faster infusion rates. Even the potential for hyperphosphatemia from the release of phosphate is generally inconsequential.
Over the last 5 years, the use of neuraminidase inhibitors for the treatment of influenza has skyrocketed. Emergency physicians have been pushed to prescribe these medications under the belief that they reduced symptoms, the risk of complications, hospitalizations, and transmission. However, the recommendation for the use of these drugs has never sat on firm evidence-based ground. So what did we know then, and what do we know now?
(more…)
Fluoroquinolones are a widely used class of antibiotic that are effective in treating a wide variety of infections. Despite their popularity there is increasing concern regarding to the potential complications associated with these agents. In 2008, the U.S. Food and Drug Administration (FDA) issued a black box warning involving fluoroquinolone use and an increased risk of tendon rupture. More recently in 2013 the FDA released another warning regarding the risk of peripheral neuropathy and required additional warnings to be added to the drug labels [1].
There is significant practice variability when providers are asked to determine if a patient is intoxicated. Some providers will evaluate a patient to determine if a patient is “clinically sober”, while other providers will rely on a patient’s blood alcohol concentration (BAC) to evaluate a patient’s level of intoxication. There is very little data to suggest that either approach is superior; however, both practice patterns have significant limitations and carry a certain degree of medicolegal risk.
Don’t know when to use ketofol for procedure sedation or if you can rapidly load phenytoin? See the new PV-Plus Cards on AgileMD for free on any smartphone/tablet/desktop. Other topics include:
UPDATE Jan 1, 2018: The PV Cards are no longer on AgileMD.